Abstract
Melatonin, a hormone important in the sleep–wake cycle, has beenused since the early 1990s in the treatment of sleep disorders in young adults and children suffering with neurological or neurode- velopmental disabilities and/or visual impairment.1 The use of Melatonin in children with Neurodevelopmental Disorders andimpaired Sleep (MENDS) trial, a randomised double-blind placebo-controlled study, is currently under way, investigating theefficacy and safety of melatonin in children.2 However, at present there is no licensed formulation of melatonin available in the UK.The aim of the study was to identify how melatonin is being used in UK hospitals in terms of the dosage, range of formulations and the companies used, as well as issues with its administration. Qualitative data among parents of childrentaking melatonin relating to its use were also sought.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
